In patients undergoing multiallergen oral immunotherapy (mOIT), the addition of dupilumab (Dupixent) after omalizumab (Xolair) has shown promise for reducing gastrointestinal adverse events during ongoing mOIT.[1] The study was presented at a meeting in Philadelphia, according to MedPage Today. Combining these biologics may improve the tolerability of immunotherapy for multiple food allergies. In related cases, dupilumab was administered initially at a dose of 600 mg subcutaneously, then 300 mg every 2 weeks, and later omalizumab 300 mg monthly was added.[1] After 6 months of combined treatment, no adverse events associated with the simultaneous use of both drugs were observed in patients.[1] In another study of 23 patients on dual biologic therapy (omalizumab and dupilumab), the median duration of treatment was 7 months, with 65% of patients continuing treatment and the majority achieving improvement.[2] The combination is considered safe, although data are limited.[3]